Oncology · 2013 · 15 citations · 29 references
MedicineOncologySurgeryMedical OncologyMetastasisSurgical OncologyCutaneous Metastatic DiseaseMalignant NeoplasmsSkin TumorsSoft Tissue SarcomasAngiosarcoma TherapyClinicopathologic FeaturesNegative Surgical MarginsPositive Surgical MarginsPrognosis Of Cutaneous MetastasesSoft Tissue Sarcoma TreatmentSurgical Resection Margins
BACKGROUND: Angiosarcoma (AS) is an uncommon soft tissue sarcoma with dismal prognosis that presents either cutaneously (C-AS) or non-cutaneously (NC-AS). We compared the clinical features and treatment outcomes between these 2 groups. METHODS: A single-centre study evaluating 60 AS patients between 2002 and 2012 was performed. RESULTS: The median age was 70 years. C-AS of the scalp or face comprised 66% of patients. C-AS patients were older than NC-AS (median age 74 vs. 56 years; p < 0.001). Proportionately more C-AS patients presented with non-metastatic disease (86 vs. 50%; p = 0.007). Amongst resected C-AS and NC-AS patients, rates of positive surgical margins (53 vs. 50%; p = 1.00) and adjuvant therapy (25 vs. 43%; p = 0.626) were not significantly different, though proportionately fewer C-AS patients relapsed (36 vs. 78%; p = 0.038). Paclitaxel was the most common agent in first line palliative systemic therapy, achieving an objective response rate of 56%. Median overall survival was 11.2 months, with no significant difference between C-AS and NC-AS (11.3 vs. 9.8 months; p = 0.895). CONCLUSION: Distinct from AS in the West, our series demonstrates a clear preponderance of scalp AS. Disparities in clinical characteristics between C-AS and NC-AS did not translate into survival differences.
29
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Sarcoma in irradiated bone. Report of eleven cases
William G. Cahan, Helen Q. Woodard, Norman L. Higinbotham et al. · Cancer · 1948 · 1.1K citations
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel, Binh Bui, Jacques‐Olivier Bay et al. · Journal of Clinical Oncology · 2008 · 693 citations · Full text
Medicine, Oncology, Pharmacology +10